MX2009004054A - 1,5-difenil-3-bencilamino-1,5-dihidropirrolidin-2-ona como moduladores de receptor de cb1. - Google Patents
1,5-difenil-3-bencilamino-1,5-dihidropirrolidin-2-ona como moduladores de receptor de cb1.Info
- Publication number
- MX2009004054A MX2009004054A MX2009004054A MX2009004054A MX2009004054A MX 2009004054 A MX2009004054 A MX 2009004054A MX 2009004054 A MX2009004054 A MX 2009004054A MX 2009004054 A MX2009004054 A MX 2009004054A MX 2009004054 A MX2009004054 A MX 2009004054A
- Authority
- MX
- Mexico
- Prior art keywords
- compounds
- antipsychotics
- blockade
- schizophrenia
- mammals
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 102000009132 CB1 Cannabinoid Receptor Human genes 0.000 abstract 1
- 108010073366 CB1 Cannabinoid Receptor Proteins 0.000 abstract 1
- 208000028698 Cognitive impairment Diseases 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 230000008484 agonism Effects 0.000 abstract 1
- 239000000164 antipsychotic agent Substances 0.000 abstract 1
- 229940005529 antipsychotics Drugs 0.000 abstract 1
- 230000037396 body weight Effects 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 230000000116 mitigating effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 230000004584 weight gain Effects 0.000 abstract 1
- 235000019786 weight gain Nutrition 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/36—Oxygen or sulfur atoms
- C07D207/38—2-Pyrrolones
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Nutrition Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Compuestos y composiciones farmacéuticas de Fórmula (I) por bloqueo de los receptores CB1 vía un mecanismo de agonismo inverso, el cual se usa para reducir peso corporal en mamíferos, deterioro cognitivo asociado con esquizofrenia, mitigar la ganancia de peso inesperado por tratamiento durante el tratamiento con antipsicóticos y tienen biodisponibilidad incrementada. (ver fórmula (I)).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US86254006P | 2006-10-23 | 2006-10-23 | |
PCT/US2007/082042 WO2008070306A2 (en) | 2006-10-23 | 2007-10-22 | 1,5-diphenyl-3-benzylamin0-1,5-dihydr0pyrr0lidin-2-0ne as cb1 receptor modulators |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2009004054A true MX2009004054A (es) | 2009-04-27 |
Family
ID=39386481
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2009004053A MX2009004053A (es) | 2006-10-23 | 2007-10-22 | 1,5-difenil-3-piridinilamino-1,5-dihidropirrolidin-2-ona como modulador de receptor de cb1. |
MX2009004054A MX2009004054A (es) | 2006-10-23 | 2007-10-22 | 1,5-difenil-3-bencilamino-1,5-dihidropirrolidin-2-ona como moduladores de receptor de cb1. |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2009004053A MX2009004053A (es) | 2006-10-23 | 2007-10-22 | 1,5-difenil-3-piridinilamino-1,5-dihidropirrolidin-2-ona como modulador de receptor de cb1. |
Country Status (23)
Country | Link |
---|---|
US (2) | US8168659B2 (es) |
EP (2) | EP2094684B1 (es) |
JP (2) | JP5331002B2 (es) |
KR (2) | KR101088229B1 (es) |
CN (2) | CN101528733B (es) |
AR (1) | AR063497A1 (es) |
AT (1) | ATE492543T1 (es) |
AU (1) | AU2007329808B2 (es) |
BR (1) | BRPI0717347A2 (es) |
CA (2) | CA2667210C (es) |
CL (1) | CL2007003002A1 (es) |
CY (1) | CY1111140T1 (es) |
DE (1) | DE602007011495D1 (es) |
DK (2) | DK2094684T3 (es) |
EA (2) | EA015175B1 (es) |
ES (2) | ES2356025T3 (es) |
MX (2) | MX2009004053A (es) |
PE (1) | PE20080926A1 (es) |
PL (2) | PL2094684T3 (es) |
PT (2) | PT2094684E (es) |
SI (2) | SI2094684T1 (es) |
TW (1) | TW200825067A (es) |
WO (2) | WO2008070305A2 (es) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR063497A1 (es) * | 2006-10-23 | 2009-01-28 | Lilly Co Eli | Compuesto de pirrodinil -2-ona, intermediario para la sintesis del mismo, composicion farmaceutica que lo comprende y su uso para preparar un medicamento |
MX2010011546A (es) * | 2008-04-22 | 2010-11-09 | Lilly Co Eli | Compuestos de 1,5-difenil-pirrolidin-2-ona como ligandos de cb-1. |
DK2280961T3 (da) | 2008-04-22 | 2012-08-27 | Lilly Co Eli | 1,5-diphenyl-pyrrolidin-2-on-forbindelser som cb-1-ligander |
WO2010057000A2 (en) * | 2008-11-13 | 2010-05-20 | The Trustees Of Columbia University In The City Of New York | Neuraminidase inhibitors and uses thereof |
CA2805091A1 (en) | 2010-07-15 | 2012-01-19 | Oleg Iliich Epshtein | Pharmaceutical compositions comprising a homopathically potentized form of an antibody to human cannabinoid receptor |
WO2014078568A1 (en) | 2012-11-14 | 2014-05-22 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
WO2022132803A1 (en) * | 2020-12-14 | 2022-06-23 | The Board Of Trustees Of The Leland Stanford Junior University | Cb2 receptor agonists |
WO2023205180A1 (en) | 2022-04-19 | 2023-10-26 | Nurix Therapeutics, Inc. | Biomarkers for cbl, and compositions and methods for their use |
US20230414598A1 (en) | 2022-06-22 | 2023-12-28 | Nurix Therapeutics, Inc. | Combination therapies with cbl-b inhibitor compounds and antiemetic agents |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW200533657A (en) * | 2004-02-17 | 2005-10-16 | Esteve Labor Dr | Substituted pyrazoline compounds, their preparation and use as medicaments |
KR20060131908A (ko) | 2004-02-19 | 2006-12-20 | 솔베이 파마슈티칼스 비. 브이 | Cb1-길항 활성을 갖는 이미다졸린 유도체 |
US20060035245A1 (en) * | 2004-04-20 | 2006-02-16 | Ason Brandon L | Modulators of enzymatic nucleic acid elements mobilization |
WO2007020502A2 (en) * | 2005-08-16 | 2007-02-22 | Pharmacia & Upjohn Company Llc | Cannabinoid receptor ligands and uses thereof |
AR063497A1 (es) * | 2006-10-23 | 2009-01-28 | Lilly Co Eli | Compuesto de pirrodinil -2-ona, intermediario para la sintesis del mismo, composicion farmaceutica que lo comprende y su uso para preparar un medicamento |
-
2007
- 2007-10-18 AR ARP070104628A patent/AR063497A1/es unknown
- 2007-10-18 CL CL200703002A patent/CL2007003002A1/es unknown
- 2007-10-18 TW TW096139051A patent/TW200825067A/zh unknown
- 2007-10-18 PE PE2007001418A patent/PE20080926A1/es not_active Application Discontinuation
- 2007-10-22 WO PCT/US2007/082041 patent/WO2008070305A2/en active Application Filing
- 2007-10-22 JP JP2009533586A patent/JP5331002B2/ja not_active Expired - Fee Related
- 2007-10-22 US US12/441,570 patent/US8168659B2/en not_active Expired - Fee Related
- 2007-10-22 ES ES07871197T patent/ES2356025T3/es active Active
- 2007-10-22 DK DK07871197.5T patent/DK2094684T3/da active
- 2007-10-22 SI SI200730538T patent/SI2094684T1/sl unknown
- 2007-10-22 EP EP07871197A patent/EP2094684B1/en not_active Not-in-force
- 2007-10-22 US US12/444,692 patent/US7998985B2/en not_active Expired - Fee Related
- 2007-10-22 PL PL07871197T patent/PL2094684T3/pl unknown
- 2007-10-22 ES ES07871196T patent/ES2398388T3/es active Active
- 2007-10-22 DE DE602007011495T patent/DE602007011495D1/de active Active
- 2007-10-22 CA CA2667210A patent/CA2667210C/en not_active Expired - Fee Related
- 2007-10-22 PT PT07871197T patent/PT2094684E/pt unknown
- 2007-10-22 JP JP2009533585A patent/JP5331001B2/ja not_active Expired - Fee Related
- 2007-10-22 SI SI200731118T patent/SI2099784T1/sl unknown
- 2007-10-22 KR KR1020097008216A patent/KR101088229B1/ko not_active IP Right Cessation
- 2007-10-22 MX MX2009004053A patent/MX2009004053A/es active IP Right Grant
- 2007-10-22 AU AU2007329808A patent/AU2007329808B2/en not_active Ceased
- 2007-10-22 AT AT07871197T patent/ATE492543T1/de active
- 2007-10-22 PT PT78711967T patent/PT2099784E/pt unknown
- 2007-10-22 CA CA2667372A patent/CA2667372C/en not_active Expired - Fee Related
- 2007-10-22 DK DK07871196.7T patent/DK2099784T3/da active
- 2007-10-22 EP EP07871196A patent/EP2099784B1/en not_active Not-in-force
- 2007-10-22 PL PL07871196T patent/PL2099784T3/pl unknown
- 2007-10-22 CN CN2007800394514A patent/CN101528733B/zh not_active Expired - Fee Related
- 2007-10-22 WO PCT/US2007/082042 patent/WO2008070306A2/en active Application Filing
- 2007-10-22 BR BRPI0717347-4A2A patent/BRPI0717347A2/pt not_active IP Right Cessation
- 2007-10-22 EA EA200970405A patent/EA015175B1/ru not_active IP Right Cessation
- 2007-10-22 EA EA200970404A patent/EA015745B1/ru not_active IP Right Cessation
- 2007-10-22 MX MX2009004054A patent/MX2009004054A/es active IP Right Grant
- 2007-10-22 CN CN2007800394497A patent/CN101528732B/zh not_active Expired - Fee Related
- 2007-10-22 KR KR1020097008214A patent/KR101088236B1/ko not_active IP Right Cessation
-
2011
- 2011-01-27 CY CY20111100093T patent/CY1111140T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2009004054A (es) | 1,5-difenil-3-bencilamino-1,5-dihidropirrolidin-2-ona como moduladores de receptor de cb1. | |
MX2010010407A (es) | Derivados de 4-aminociclohexanos sustituidos. | |
MX2009005252A (es) | Aminopirrolidinas como antagonistas del receptor de quimiocina. | |
ME01532B (me) | Jedinjenja | |
MX346608B (es) | Compuestos de isoindol 5-sustituidos. | |
WO2007133802A3 (en) | Pharmaceutical formulations of pimavanserin | |
TW200640867A (en) | Pyridine-3-carboxamide derivatives as CB1 inverse agonists | |
HK1158192A1 (en) | Piperidine gpcr agonists | |
MY150518A (en) | Substituted gamma lactams as therapeutic agents | |
GB0812642D0 (en) | Compounds | |
MX2009003316A (es) | Derivados de pirazina-2-carboxamida como moduladores receptores de cb2. | |
MA32467B1 (fr) | Derives de piperidinyle agonistes de gpcr | |
MX2009007180A (es) | Agonistas del receptor acoplado a la proteina g de la piperidina. | |
MX2010009646A (es) | Agentes terapeuticos antivirales. | |
MX2007011023A (es) | 2-(4-oxo-4h-quinazolin-3-il) acetamidas y su uso como antagonistas de vasopresin v3. | |
SG170752A1 (en) | Benzimidazoles which have activity at m1 receptor and their uses in medicine | |
MX2012002366A (es) | Agonistas novedosos de receptores beta 3 andrenergicos derivados de pirrolidina. | |
MX2008013196A (es) | 5-amido-2-carboxiamida-indoles. | |
IN2012DN02556A (es) | ||
TW200736233A (en) | Cyclohexyl piperazinyl methanone derivatives | |
TW200942535A (en) | Novel compounds as cannabinoid receptor ligands | |
DOP2011000081A (es) | Benzamida sustituida como ligandos del receptor de canabinoides | |
IL193479A0 (en) | Modulators of muscarinic receptors | |
PH12013502616A1 (en) | Cyclopropyl amide derivatives 978 | |
MY152030A (en) | Novel herbicides |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |